Cutaneous leishmaniasis. Treatment with itraconazole

Albanese, G.

doi:10.1001/archderm.125.11.1540

Cited by 15 publications

(12 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[85][86][87][88][89][90][91] Initially, only case reports were available, but after 10 years in vitro testing began. 89,[92][93][94][95] The experimental results were not satisfactory, but clinical tests indicated promising results for this drug as a last resort in relapsing cases. 96 Therefore, more studies were carried out focusing on the treatment of ATL.…”

Section: Discussionmentioning

confidence: 97%

Treatment of New World cutaneous leishmaniasis – a systematic review with a meta‐analysis

et al. 2008

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 97%

Treatment of New World cutaneous leishmaniasis – a systematic review with a meta‐analysis

et al. 2008

View full text Add to dashboard Cite

show abstract

“…Similar results to those obtained here with the standard treatment here (Group 1) were also achieved by our research team in 2002 31 while treating 29 patients from the municipality of Araçuaí, State of Minas Gerais. These patients had no indication for treatment with the standard antimonial therapy, mainly due to the presence of electrocardiographic alterations (17), antimony allergy (4), pregnancy (6) and nephropathy (2). Among these patients, 10 underwent immunochemotherapy and another 19 immunotherapy.…”

Section: Resultsmentioning

confidence: 99%

“…Since the introduction of antimonial drugs for leishmaniasis therapy, which have also been shown to produce divergent results 2 35 36 , and proved by Antunes et al 4 and Armijos et al 5 , its therapeutic use has been under study, whether alone or associated with other drugs; and it has also been regarded as one of the current treatments, as well as one of the available prophylactic measures for ACL 14 22 28 35 39 43 .…”

mentioning

confidence: 99%

Immunotherapy, immunochemotherapy and chemotherapy for American cutaneous leishmaniasis treatment

Mayrink

Botelho

Magalhães

et al. 2006

Rev. Soc. Bras. Med. Trop.

View full text Add to dashboard Cite

The first choice of treatment for American cutaneous leishmaniasis is the pentavalent antimonial drug. Although it has been shown that this treatment is mostly effective and indicated, some disadvantages should be taken into account such as side effects, long term treatment inconveniences and counter-indication for patients suffering from cardiopathy, nephropathy; yet, aging, pregnancy and other conditions. With the advent of the vaccine anti-American cutaneous leishmaniasis as a prophylactic measure, studies on therapy using the vaccine associated or not with other drugs have been performed by many investigators and it is currently among the alternative treatments and prevention measures for American cutaneous leishmaniasis. In conclusion, the association between antimony and vaccine (immunochemotherapy) showed the same cure rate when compared with the standard treatment (100%) and it was also able to reduce the salt volume in 17.9% and treatment length from 87 to 62 days, decreasing side effects. Key-words: American cutaneous leishmaniasis. Treatment. Immunotherapy. RESUMOO tratamento de primeira escolha para leishmaniose tegumentar americana é o antimonial pentavalente. Embora este tratamento seja na maioria das vezes efetivo e indicado, devem ser consideradas as desvantagens tais como efeitos colaterais, longa duração do tratamento e contra-indicação para cardiopatas, nefropatas, idosos, grávidas e outras condições. Com o advento da vacina antileishmaniose tegumentar americana para fins profiláticos e terapêuticos, associando-a ou não a outros fármacos, muitas pesquisas têm sido desenvolvidas, sendo a vacina a principal entre os atuais recursos no tratamento e prevenção da leishmaniose tegumentar americana. Em conclusão, a associação do antimônio com a vacina (imunoquimioterapia) apresentou o mesmo índice de cura em relação ao tratamento padrão (100%), e ainda reduziu o volume do sal em 17,9% e o tempo de cura significativamente, de 87 para 62 dias; conseqüentemente, reduzindo os efeitos colaterais. Palavras-chaves: Leishmaniose tegumentar americana. Tratamento. Imunoterapia.

show abstract

“…Miltefosine-resistant Leishmania donovani promastigotes also demonstrated modification in sterol biosynthesis and lipid compositions which influences the membrane fluidity and permeability and ultimately may affect drug-membrane interactions [5]. Other possible oral treatments for CL include azole antifungals that show in vitro [12] and in vivo activity against Leishmania [13][14][15][16][17][18][19][20]. Triazoles antifungals inhibit 14α-lanosterol demethylation, causing accumulation of 14α-methyl sterols blocking the synthesis of ergosterol, the main sterol of Leishmania such as fluconazole, eliminating promastigote and amastigote of Leishmania sp.…”

Section: Introductionmentioning

confidence: 99%

Utility of amino acid coupled 1,2,4-triazoles in organic synthesis: synthesis of some new antileishmainal agents

El‐Saghier¹,

Mohamed²,

Abdalla³

et al. 2018

Bull. Chem. Soc. Eth.

View full text Add to dashboard Cite

Starting from 3-amino-5-(2-hydroxyphenyl) amino acid coupled triazoles 1a-e, new 3-(2hydroxyphenyl)-3H-imidazo[2,1-c][1,2,4]triazol-6(5H)-one 2a,b, 3b,d, 6a and 3-N-arly(alkyl) amino acid coupled triazoles 4b,d, 7a,c,d,e have been synthesized as potential antileishmanial agents. The structures of the newly synthesized compounds were confirmed using elemental and spectral analyses (FT-IR, 1 H-NMR, 13 C-NMR and MS). The in vitro antileishmanial potency of the synthesized compounds was evaluated compared to Amphotericin B deoxycholate and miltefosine as lead references. Compounds 2b, 7d and 7e showed perfect IC50 values corresponding to amphotericin B and more patent than miltefosine against L. aethiopica promastigotes.

show abstract

Cutaneous leishmaniasis. Treatment with itraconazole

Cited by 15 publications

References 0 publications

Treatment of New World cutaneous leishmaniasis – a systematic review with a meta‐analysis

Treatment of New World cutaneous leishmaniasis – a systematic review with a meta‐analysis

Immunotherapy, immunochemotherapy and chemotherapy for American cutaneous leishmaniasis treatment

Utility of amino acid coupled 1,2,4-triazoles in organic synthesis: synthesis of some new antileishmainal agents

Contact Info

Product

Resources

About